CU24518B1 - Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina - Google Patents

Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina

Info

Publication number
CU24518B1
CU24518B1 CU2019000035A CU20190035A CU24518B1 CU 24518 B1 CU24518 B1 CU 24518B1 CU 2019000035 A CU2019000035 A CU 2019000035A CU 20190035 A CU20190035 A CU 20190035A CU 24518 B1 CU24518 B1 CU 24518B1
Authority
CU
Cuba
Prior art keywords
pyrimidin
amine
pirazol
substitute derivatives
compounds
Prior art date
Application number
CU2019000035A
Other languages
English (en)
Other versions
CU20190035A7 (es
Inventor
Dr Anna Lena Andreevski
Dr Karl Collins
Dr Andre Philippe Dieskau
Dr Jan Dreher
Dr Alexander Ehrmann
Dr David Engel
Dra Anja Giese
Dr Alexey Gromov
Dr Antje Kahnert
Dr Jürgen Klar
Niels Lindner
Dr Thomas Müller
Dr Carsten Schmeck
Dr Jens Willwacher
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20190035A7 publication Critical patent/CU20190035A7/es
Publication of CU24518B1 publication Critical patent/CU24518B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere a compuestos sustituidos de 6-(1 H-pirazol-1-il)pirimidin-4-amina de la fórmula general (I) tal como se describen y definen en el presente, a procedimientos para preparar dichos compuestos, y a compuestos intermedios útiles para preparar dichos compuestos.</p>
CU2019000035A 2016-10-14 2017-10-09 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina CU24518B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16193953 2016-10-14
PCT/EP2017/075630 WO2018069222A1 (en) 2016-10-14 2017-10-09 Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
CU20190035A7 CU20190035A7 (es) 2019-11-04
CU24518B1 true CU24518B1 (es) 2021-06-08

Family

ID=57136772

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000035A CU24518B1 (es) 2016-10-14 2017-10-09 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina

Country Status (28)

Country Link
US (2) US11208400B2 (es)
EP (1) EP3526212B1 (es)
JP (1) JP2019532961A (es)
KR (1) KR20190065402A (es)
CN (1) CN110191884A (es)
AR (1) AR109947A1 (es)
AU (1) AU2017341324A1 (es)
BR (1) BR112019007496A2 (es)
CA (1) CA3040166A1 (es)
CL (1) CL2019001004A1 (es)
CO (1) CO2019003761A2 (es)
CR (1) CR20190192A (es)
CU (1) CU24518B1 (es)
DO (1) DOP2019000099A (es)
EA (1) EA201990947A1 (es)
EC (1) ECSP19026563A (es)
GE (2) GEAP202115076A (es)
IL (1) IL265923A (es)
JO (1) JOP20190080A1 (es)
MA (1) MA46514A (es)
MX (1) MX381873B (es)
PE (1) PE20191549A1 (es)
PH (1) PH12019500808A1 (es)
SG (1) SG11201903305XA (es)
TN (1) TN2019000114A1 (es)
TW (1) TW201825477A (es)
UY (1) UY37444A (es)
WO (1) WO2018069222A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110734428A (zh) * 2019-10-24 2020-01-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN115403524A (zh) * 2021-05-26 2022-11-29 浙江省化工研究院有限公司 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法
CN119894870A (zh) 2022-09-19 2025-04-25 巴斯夫欧洲公司 唑杀有害生物化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
HK1041703A1 (zh) 1999-01-21 2002-07-19 Board Of Regents The University Of Texas System 肠道顶膜钠/磷酸盐共同传送的抑制剂
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
JP2008296610A (ja) 2007-05-29 2008-12-11 Toyota Motor Corp 車両用動力伝達装置の制御装置
JP5539963B2 (ja) * 2008-04-29 2014-07-02 ノバルティス アーゲー 線維芽細胞増殖因子受容体のキナーゼ活性のモジュレーションをモニタリングする方法、および該方法の使用
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA026692B1 (ru) * 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
WO2012006475A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827326B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2012329913A1 (en) 2011-10-27 2014-05-22 Astellas Pharma Inc. Aminoalkyl-substituted N-thienyl benzamide derivative
WO2013082756A1 (en) 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors ii
WO2014152716A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
TWI582083B (zh) * 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
EA032137B1 (ru) 2014-11-03 2019-04-30 Байер Фарма Акциенгезельшафт Производные гидроксиалкил-замещенного фенилтриазола и их применение
CN105631664A (zh) 2014-11-26 2016-06-01 华为终端（东莞）有限公司 一种非接触支付方法、装置及系统
US10266517B2 (en) * 2014-12-23 2019-04-23 Dana-Farber Cancer Institute, Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2949414T3 (es) 2016-10-14 2023-09-28 Novartis Ag Formas cristalinas de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida
ES2945822T3 (es) 2016-10-14 2023-07-07 Inst Pasteur De Montevideo Moduladores antinflamatorios y metabólicos pluripotentes para el tratamiento de afecciones relacionadas con la inflamación

Also Published As

Publication number Publication date
DOP2019000099A (es) 2019-07-15
US20200055842A1 (en) 2020-02-20
CN110191884A (zh) 2019-08-30
TN2019000114A1 (en) 2020-10-05
EA201990947A1 (ru) 2019-08-30
BR112019007496A2 (pt) 2019-09-10
PH12019500808A1 (en) 2020-01-20
CA3040166A1 (en) 2018-04-19
KR20190065402A (ko) 2019-06-11
TW201825477A (zh) 2018-07-16
UY37444A (es) 2018-05-31
IL265923A (en) 2019-06-30
EP3526212B1 (en) 2021-12-22
US20230065629A1 (en) 2023-03-02
AU2017341324A1 (en) 2019-05-02
CU20190035A7 (es) 2019-11-04
CL2019001004A1 (es) 2019-08-30
MX381873B (es) 2025-03-13
US11208400B2 (en) 2021-12-28
WO2018069222A1 (en) 2018-04-19
CO2019003761A2 (es) 2019-04-30
EP3526212A1 (en) 2019-08-21
MX2019004347A (es) 2019-07-01
ECSP19026563A (es) 2019-04-30
JP2019532961A (ja) 2019-11-14
MA46514A (fr) 2019-08-21
GEAP202115076A (en) 2021-01-25
CR20190192A (es) 2019-09-02
PE20191549A1 (es) 2019-10-24
JOP20190080A1 (ar) 2019-04-11
AR109947A1 (es) 2019-02-06
SG11201903305XA (en) 2019-05-30
GEP20217269B (en) 2021-06-25

Similar Documents

Publication Publication Date Title
CU24612B1 (es) Derivados de piridazinas sustituidas útiles como herbicidas
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
NZ726356A (en) Processes for preparing antiviral compounds
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
MX2017003695A (es) Pirimidinonas como inhibidores del factor xia.
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
DOP2016000242A (es) Uso de compuestos heterocíclicos para controlar nematodos
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
CL2019001736A1 (es) Polimorfos.
CL2019001737A1 (es) Polimorfos.
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
CL2018002094A1 (es) Un proceso para preparar compuesto de pirrolo[3,2–d]pirimidina y su intermediario